Relieves ocular itching due to seasonal allergic conjunctivitis. ANDA 76109, held by Apotex. Ketorolac Tromethamine.
As of Nov 21, 2026, ANDA 76109 (Ketorolac Tromethamine), held by Apotex, was first approved by FDA on Nov 5, 2009, with 4 approved supplements and 0 published complete response letters.
Ketorolac tromethamine ophthalmic solution is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. Ketorolac tromethamine ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. Ketorolac tromethamine ophthalmic solution is a nonsteroidal, anti-inflammatory indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 5, 2009 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ketorolac Tromethamine0.5% · solution/drops;ophthalmic | Ketorolac Tromethamine | Rx |
| Jan 22, 2026 | Supplement 19Labeling · Standard review | Approved | None posted |
| Sep 5, 2018 | Supplement 12Manufacturing | Approved | None posted |
| Dec 11, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Mar 28, 2013 | Supplement 1Manufacturing | Approved | None posted |
| Nov 5, 2009 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters